The association between Hirschsprung’s disease and multiple endocrine neoplasia type 2a: a systematic review
- 619 Downloads
The co-occurrence of Hirschsprung’s disease (HSCR) and multiple endocrine neoplasia type 2 (MEN2) is a relatively rare event. The basis for this association is the presence of a “Janus” mutation in the RET proto-oncogene––a mutation that acts simultaneously as both a gain-in-function and a loss-of-function mutation. To date, four mutations in the exon 10 region of RET that are known to cause MEN2A have been implicated in this association: C620, C618, C611 and C609. We performed a systematic review of the published literature on this association to determine its incidence, the prevalence and phenotype of HSCR associated with the 4 RET mutations mentioned above.
A systematic literature-based search for relevant articles was conducted using three online databases. After exclusion of ineligible publications, we recorded data on all patients with a diagnosis of HSCR or MEN2A with a “Janus” RET mutation, as well as those who carried the mutation but were unaffected. Statistical analysis was performed using SPSS.
The literature search yielded 885 publications, of which 36 articles, incorporating data on 341 individuals, were eligible for inclusion in the final analysis. Co-occurrence of HSCR and MEN2A was recorded in 84 cases (24.6 %). HSCR occurred alone in 64 carriers of a “Janus” mutation (18.8 %) and MEN2A occurred in isolation in 173 cases (50.7 %). Twenty individuals (5.9 %) were found to carry a “Janus” mutation after screening on the basis of family history but were unaffected by either MEN2A or HSCR. The most common mutation recorded was the C620 mutation [114 cases (48.1 %)]. There was a relatively high incidence of long-segment aganglionosis (29.3 %) and total colonic aganglionosis (17.3 %) in this cohort. This trend was particularly notable in those with C620 mutations, only 33 % of whom had short-segment disease.
While the overall incidence of HSCR co-occurring with MEN2A is low, both conditions occur with a relatively high frequency in families with a RET mutation at exon 10. The proportion of cases of long-segment HSCR and total colonic aganglionosis is higher than that in the general population with HSCR in those with C620 and C618 mutations. These findings re-inforce the importance of RET mutation testing in HSCR when a family history of either HSCR or MEN2 is present. In families with MEN2A and known exon 10 RET mutations, the threshold for investigation for HSCR in those with gastrointestinal symptoms should be very low. High-quality prospective longitudinal studies of large HSCR populations are required to shed greater light on this rare but important phenomenon.
KeywordsHirschsprung’s Multiple endocrine neoplasia MEN2A MEN2B Janus RET
- 5.Pasini B, Rossi R, Ambrosio MR, Zatelli MC, Gullo M, Gobbo M, Collini P, Aiello A, Pansini G, Trasforini G, degli Uberti EC (2002) RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung’s disease. Surgery 131(4):373–381PubMedCrossRefGoogle Scholar
- 6.Arighi E, Popsueva A, Degl’Innocenti D, Borrello MG, Carniti C, Perala NM, Pierotti MA, Sariola H (2004) Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung’s disease. Mol Endocrinol 18(4):1004–1017. doi: 10.1210/me.2003-0173 PubMedCrossRefGoogle Scholar
- 8.Emison ES, Garcia-Barcelo M, Grice EA, Lantieri F, Amiel J, Burzynski G, Fernandez RM, Hao L, Kashuk C, West K, Miao X, Tam PK, Griseri P, Ceccherini I, Pelet A, Jannot AS, de Pontual L, Henrion-Caude A, Lyonnet S, Verheij JB, Hofstra RM, Antinolo G, Borrego S, McCallion AS, Chakravarti A (2010) Differential contributions of rare and common, coding and noncoding ret mutations to multifactorial Hirschsprung disease liability. Am J Hum Genet 87(1):60–74. doi: 10.1016/j.ajhg.2010.06.007 PubMedCentralPubMedCrossRefGoogle Scholar
- 15.Butter A, Gagne J, Al-Jazaeri A, Emran MA, Deal C, St-Vil D (2007) Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung’s disease. J Pediatr Surg 42(1):203–206. doi: 10.1016/j.jpedsurg.2006.09.019 PubMedCrossRefGoogle Scholar
- 17.Fitze G, Schreiber M, Hohenberger W, Hummer HP, Roesner D, Schackert HK (2004) Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135G>A alleles modifying MEN 2A or HSCR phenotypes. Am J Med Genet Part A 129A(3):323–325. doi: 10.1002/ajmg.a.30230 PubMedCrossRefGoogle Scholar
- 27.Peretz H, Luboshitsky R, Baron E, Biton A, Gershoni R, Usher S, Grynberg E, Yakobson E, Graff E, Lapidot M (1997) Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung’s disease suggesting a role for imprinting. Hum Mutat 10(2):155–159. doi: 10.1002/(SICI)1098-1004(1997)10:2<155:AID-HUMU7>3.0.CO;2-J PubMedCrossRefGoogle Scholar
- 29.Caron P, Attie T, David D, Amiel J, Brousset F, Roger P, Munnich A, Lyonnet S (1996) C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung’s disease. J Clin Endocrinol Metab 81(7):2731–2733. doi: 10.1210/jcem.81.7.8675603 PubMedGoogle Scholar
- 36.Oliva-Rodriguez R, Guerrero-VazquezR, Del Castillo Tous M, Martinez-Brocca MA, Martos-Martinez JM, Leal-Cerro A, Navarro-Gonzalez E (2011) Descriptive study of the clinical behavior of multiple endocrine neoplasia 2A. Endocrine reviews. https://www.endocrine.org/~/media/endosociety/Files/Meetings/Abstracts/2011/02TES2011.pdf
- 43.Decker RA (1992) Long-term follow-up of a large North American kindred with multiple endocrine neoplasia type 2A. Surg 112(6):1066–1072 (Discussion 1072–1063)Google Scholar
- 44.Hofstra RM, Wu Y, Stulp RP, Elfferich P, Osinga J, Maas SM, Siderius L, Brooks AS, vd Ende JJ, Heydendael VM, Severijnen RS, Bax KM, Meijers C, Buys CH (2000) RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems. Hum Mutat 15(5):418–429. doi: 10.1002/(SICI)1098-1004(200005)15:5<418:AID-HUMU3>3.0.CO;2-2 PubMedCrossRefGoogle Scholar
- 45.Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276(19):1575–1579PubMedCrossRefGoogle Scholar
- 46.Carniti C, Belluco S, Riccardi E, Cranston AN, Mondellini P, Ponder BA, Scanziani E, Pierotti MA, Bongarzone I (2006) The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung’s disease. Am J Pathol 168(4):1262–1275. doi: 10.2353/ajpath.2006.050607 PubMedCentralPubMedCrossRefGoogle Scholar